UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

EP03.05-03 Hollow-MnO2 Nanofabricated Platform Equipped with Carbon Monoxide Gas Combined with SDT Enhanced ROS Generator for Lung Cancer Treatment

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S448-S449

2023

Volltextzugriff (PDF)

EP08.02-160 A Pooled Efficacy and Safety Analysis of Anlotinib Plus Docetaxel in Advanced NSCLC Previously Treated with Immunotherapy

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S482-S483

2022

Volltextzugriff (PDF)

P13.02 Role of Management Checklist in the Prevention and Control of NCP in Oncology Ward

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S326-S327

2021

Volltextzugriff (PDF)

P88.05 A Recommended one-step Targeted Sequencing Technology for Identification of a Dual CD74-ROS1 in NSCLC

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S687-S688

2021

Volltextzugriff (PDF)

P86.22 Anlotinib plus Docetaxel versus Docetaxel as 2nd Line Treatment in Advanced Non-Small Cell Lung Cancer: A Phase I/II Study

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S682-S682

2021

Volltextzugriff (PDF)

P86.20 The Prevalence of NTRK1 Fusion in a Chinese Lung Cancer Cohort

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S681-S681

2021

Volltextzugriff (PDF)

EP1.03-09 Epidemiological Study of TSC1 Mutations Among Non-Small Cell Lung Cancer Patients in China

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S956-S957

2019

Volltextzugriff (PDF)

EP08.01-097 Landscape and Dynamic Changes of Peripheral Immune Cells in Non-small Cell Lung Cancer Patients with First-line Immunotherapy

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S389

2022

Volltextzugriff (PDF)

MA13.01 Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Non-Squamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial

Journal of thoracic oncology, 2021-10, Vol.16 (10), p.S924-S924

2021

Volltextzugriff (PDF)

96O Camrelizumab or placebo plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-sq): A randomized, double-blind, multicenter, phase III trial

Journal of thoracic oncology, 2021-04, Vol.16 (4), p.S748-S748

2021

Volltextzugriff (PDF)

MA19.09 AI-Based Early Detection and Subtyping of Non-Small Cell Lung Cancer from Blood Samples Using Orphan Noncoding RNAs

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S173

2023

Volltextzugriff (PDF)

PS02.15 Evaluating the Uptake of Newly Marketed Drugs Using Real-World Data: An Example of Anti-PD-1s in Advanced Non-Small Cell Lung Cancer: Topic: Medical Oncology

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S1569-S1570

2017

Volltextzugriff (PDF)

PS02.15 Evaluating the Uptake of Newly Marketed Drugs Using Real-World Data: An Example of Anti-PD-1s in Advanced Non-Small Cell Lung Cancer

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S1569-S1570

2017

Volltextzugriff (PDF)

IA34 The YAP/FOXM1 Axis Regulates EMT-Associated EGFR Tyrosine Kinase Inhibitor Resistance and Increased Expression of Spindle Assembly Checkpoint Components

Journal of thoracic oncology, 2020-02, Vol.15 (2), p.S11-S11

2020

Volltextzugriff (PDF)

161P Real-world large-scale study of KRAS fusions in Chinese non-small cell lung cancer patients: A multicenter study (Yangtze River Delta Lung Cancer Cooperation Group-002)

Journal of thoracic oncology, 2021-04, Vol.16 (4), p.S786-S786

2021

Volltextzugriff (PDF)

Epidemiological Study of TSC1 Mutations Among Non-Small Cell Lung Cancer Patients in China: EP1.03-09

Journal of thoracic oncology, 2019-10, Vol.14 (10 Suppl), p.S956-S957

2019

Volltextzugriff (PDF)

P1.26-01 A Real World Study of Perioperative Outcomes after Minimally Invasive Segmentectomy versus Lobectomy for Early-Stage Lung Cancer

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S278

2023

Volltextzugriff (PDF)

P1.17-011 Efficacy and Toxicities of Gemcitabine and Cisplatin Combination Chemotherapy in Advanced Thymoma and Thymic Carcinoma

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S2064-S2065

2017

Volltextzugriff (PDF)

MA14.05 Tumor Tissue and Plasma EGFR Exon 20 Insertion Mutation Status in NSCLC Patients Treated with Sunvozertinib

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S150

2023

Volltextzugriff (PDF)

P2.06-02 DEnosumab plus PD-1 Inhibitor for MAINtenance Therapy of Advanced KRAS-Mutant NSCLC - A Prospective, Single-Arm, Phase II Study (DEMAIN)

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S317

2023

Volltextzugriff (PDF)

EP07.05-17 Aumolertinib as Neoadjuvant Therapy for EGFR-mutated Non-Small Cell Lung Cancer: A Subcohort Analysis of the PURPOSE Trial

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S565

2023

Volltextzugriff (PDF)

EP12.02-07 The Effectiveness of Lorlatinib for Previously Treated ROS1-rearranged NSCLC: Real world Experience in Taiwan

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S676-S677

2023

Volltextzugriff (PDF)

P11.03 SHR-1316 in Combination With Fluzoparib in Relapsed Small-Cell Lung Cancer: An Open-Label, Multicenter, Two-Stage, Phase Ⅰb Trial

Journal of thoracic oncology, 2021-10, Vol.16 (10), p.S1006-S1006

2021

Volltextzugriff (PDF)

MA01.10 MDM2 Inhibitor APG-115 Suppresses Cell Proliferation and Tumor Growth in Preclinical Models Of NSCLC Harboring STK11 Mutations

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S132-S133

2021

Volltextzugriff (PDF)

OA09.03 STK11/LKB1 Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy in NSCLC: Results From Three Randomized Trials

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S62-S63

2023

Volltextzugriff (PDF)

1 – 25 von 222

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Thoracic Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(222)
Mit Volltextzugriff
(222)

Publikationsform

Artikel
(222)

Sprache

Englisch
(222)
Japanisch
(1)

Erscheinungsjahr

n.n

Kollektion

Menü

Weitere Dienste

Einstellungen

EP03.05-03 Hollow-MnO2 Nanofabricated Platform Equipped with Carbon Monoxide Gas Combined with SDT Enhanced ROS Generator for Lung Cancer Treatment

EP08.02-160 A Pooled Efficacy and Safety Analysis of Anlotinib Plus Docetaxel in Advanced NSCLC Previously Treated with Immunotherapy

P13.02 Role of Management Checklist in the Prevention and Control of NCP in Oncology Ward

P88.05 A Recommended one-step Targeted Sequencing Technology for Identification of a Dual CD74-ROS1 in NSCLC

P86.22 Anlotinib plus Docetaxel versus Docetaxel as 2nd Line Treatment in Advanced Non-Small Cell Lung Cancer: A Phase I/II Study

P86.20 The Prevalence of NTRK1 Fusion in a Chinese Lung Cancer Cohort

EP1.03-09 Epidemiological Study of TSC1 Mutations Among Non-Small Cell Lung Cancer Patients in China

EP08.01-097 Landscape and Dynamic Changes of Peripheral Immune Cells in Non-small Cell Lung Cancer Patients with First-line Immunotherapy

MA13.01 Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Non-Squamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial

96O Camrelizumab or placebo plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-sq): A randomized, double-blind, multicenter, phase III trial

MA19.09 AI-Based Early Detection and Subtyping of Non-Small Cell Lung Cancer from Blood Samples Using Orphan Noncoding RNAs

PS02.15 Evaluating the Uptake of Newly Marketed Drugs Using Real-World Data: An Example of Anti-PD-1s in Advanced Non-Small Cell Lung Cancer: Topic: Medical Oncology

PS02.15 Evaluating the Uptake of Newly Marketed Drugs Using Real-World Data: An Example of Anti-PD-1s in Advanced Non-Small Cell Lung Cancer

IA34 The YAP/FOXM1 Axis Regulates EMT-Associated EGFR Tyrosine Kinase Inhibitor Resistance and Increased Expression of Spindle Assembly Checkpoint Components

161P Real-world large-scale study of KRAS fusions in Chinese non-small cell lung cancer patients: A multicenter study (Yangtze River Delta Lung Cancer Cooperation Group-002)

Epidemiological Study of TSC1 Mutations Among Non-Small Cell Lung Cancer Patients in China: EP1.03-09

P1.26-01 A Real World Study of Perioperative Outcomes after Minimally Invasive Segmentectomy versus Lobectomy for Early-Stage Lung Cancer

P1.17-011 Efficacy and Toxicities of Gemcitabine and Cisplatin Combination Chemotherapy in Advanced Thymoma and Thymic Carcinoma

MA14.05 Tumor Tissue and Plasma EGFR Exon 20 Insertion Mutation Status in NSCLC Patients Treated with Sunvozertinib

P2.06-02 DEnosumab plus PD-1 Inhibitor for MAINtenance Therapy of Advanced KRAS-Mutant NSCLC - A Prospective, Single-Arm, Phase II Study (DEMAIN)

EP07.05-17 Aumolertinib as Neoadjuvant Therapy for EGFR-mutated Non-Small Cell Lung Cancer: A Subcohort Analysis of the PURPOSE Trial

EP12.02-07 The Effectiveness of Lorlatinib for Previously Treated ROS1-rearranged NSCLC: Real world Experience in Taiwan

P11.03 SHR-1316 in Combination With Fluzoparib in Relapsed Small-Cell Lung Cancer: An Open-Label, Multicenter, Two-Stage, Phase Ⅰb Trial

MA01.10 MDM2 Inhibitor APG-115 Suppresses Cell Proliferation and Tumor Growth in Preclinical Models Of NSCLC Harboring STK11 Mutations

OA09.03 STK11/LKB1 Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy in NSCLC: Results From Three Randomized Trials

Aktive Filter

Suchergebnisse filtern